Patients who received lung transplants due to cystic fibrosis have been reported to have the lowest response, with one study showing that only 23.5% or 52.9%, respectively, developed an IgG (Immunoglobulin G) or IgA (Immunoglobulin A) response after the two mRNA BNT162b2 vaccine doses—the minimum requirement for current mRNA vaccines—compared to a greater than 80% response rate to either dose in patients with cystic fibrosis without lung transplant [12]. The gene discussed is CD79A; the disease is cystic fibrosis.